Tofacitinib Citrate: Janus Kinase (JAK) Inhibitor
Tofacitinib citrate is an oral, small-molecule inhibitor of the Janus kinase (JAK) family, with preferential selectivity for JAK1 and JAK3 over JAK2. By blocking JAK-dependent cytokine signaling through the JAK-STAT pathway, tofacitinib modulates the immune response involved in inflammatory and autoimmune conditions. It was first approved for rheumatoid arthritis and has since expanded into other inflammatory indications.
Product Profile
| CAS Number | 540737-29-9 |
|---|---|
| Molecular Formula | C16H20N6O · C6H8O7 |
| Appearance | White to off-white powder |
| Therapeutic Category | Immunomodulator / JAK Inhibitor |
| Storage | Store at controlled room temperature, protect from moisture |
Applications
Tofacitinib citrate is used in the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response to methotrexate. It is also approved for psoriatic arthritis and ulcerative colitis. Formulated as immediate-release and extended-release oral tablets, it provides an alternative to biologic therapy for patients who prefer oral administration. The compound is also under investigation for additional autoimmune conditions including atopic dermatitis and alopecia areata.
Why Source from TCS
TCS supplies tofacitinib citrate to pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.
FAQ
What information should be included in an inquiry for Tofacitinib Citrate 540737-29-9?
A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.
How is Tofacitinib Citrate 540737-29-9 usually evaluated for sourcing?
This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.
What documentation and commercial points are commonly reviewed before buying Tofacitinib Citrate 540737-29-9?
For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.
Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.